On the contrary, this meta-analysis by Li et al. showed that SGLT2 inhibitor use is linked to a 19.33% lower risk of serious adverse events of AF and atrial flutter (AFL) when compared with placebo. The gene discussed is SLC5A2; the disease is atrial fibrillation.